TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04296396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0 to 20 tablets of oxycodone 5mg
Description: Individualized opioid prescription protocol (IOPP) that includes shared decision making

Intervention type: DRUG
Group type: OTHER
Intervention: Fixed opioid prescription
Description: 20 tablets of oxycodone 5mg
Study: NCT02752295

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stress-coping week
Description: The multidisciplinary team will offer Mindfulness-Based Stress Reduction (MBSR), group psychotherapy (resilience, Cognitive Behavioral Analysis System of Psychotherapy CBASP, psychodynamic therapy), relaxation training, nutrition course, stress-coping and physical training in a group setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stress-coping week
Description: The multidisciplinary team will offer Mindfulness-Based Stress Reduction (MBSR), group psychotherapy (resilience, Cognitive Behavioral Analysis System of Psychotherapy CBASP, psychodynamic therapy), relaxation training, nutrition course, stress-coping and physical training in a group setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: additional two days follow-up weekend
Description: A two-days follow-up which recapitulates previous treatment elements.
Study: NCT02269891

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nu Femme
Description: Combination product of Labisia pumila and Eurycoma longifolia extracts

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04546958

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplements
Description: Nutritional counseling and whey protein supplements for 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling
Description: Nutritional counseling by dietitians for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Nutritional counseling by dietitians for 3 months
Study: NCT04285983

Intervention type: DRUG
Intervention: Trelagliptin
Description: Trelagliptin tablets
Study: NCT00006001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Study: NCT01620749

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F MEL050
Description: Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.
Study: NCT05278117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh
Description: outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh
Study: NCT03539237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video demonstration of physical activity intensity levels
Description: In the video demonstration, an approximately 50 year old male explains 1) light-intensity, 2) moderate-intensity, and 3) vigorous-intensity physical activity referring to differences in heart rate, breathing frequency and capability to talk normally. Simultaneously, on a treadmill he demonstrates the body signs of the three intensity levels. He gives examples and points out that there are individual differences in the intensity evaluation of comparable activities.
Study: NCT01072149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF)/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Study: NCT03982290

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, microcrystalline cellulose
Description: Placebo capsules, 2 capsules per day
Study: NCT02089919

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cancer stem cell vaccine
Study: NCT03812536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Void
Description: Currently the protocol at The Ohio State University Hospital requires voiding spontaneously prior to discharge from the PACU. Our intervention group will be discharged home without having to void spontaneously as a discharge criteria.
Study: NCT04322188

Intervention type: OTHER
Description: this is an observational study. No intervention is applicable; patients are managed as per clinicians' best judgement and best practice

Intervention type: OTHER
Description: this is an observational study. No intervention is applicable; patients are managed as per clinicians' best judgement and best practice
Study: NCT03140397

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6-prenylnaringenin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 8-prenylnaringenin
Study: NCT03482531

Intervention type: OTHER
Intervention: mathematical model
Description: mathematical model: regression equation that calculates the mean time from insert placement to delivery for each patient, based on every patient's characteristics (parity, BMI, cervical dilation and state of membranes)
Study: NCT02735148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Weight Supported Treadmill Training
Description: There were three intervention arms in this study,~1. Body Weight Supported Treadmill Training,~2. Conventional Training and~3. Combined Training.
Study: NCT02493036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-010
Study: NCT05663021

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided core needle biopsy in breast
Description: For patients who were not evaluated as progressive disease by the latest imaging measurement, repeated core needle biopsy is conducted within the baseline tattooed area after 2 to 4 cycles of neoadjuvant chemotherapy, depending on the total cycles of chemotherapy. Tissue is acquired from different sections of the lesion from different angles to minimize the impact of tumor heterogeneity. For each patient, 3 to 4 tissue specimens are collected and sent for pathological review to examine whether there is residual malignancy (residual cancer, pleomorphic tissue) in the tumor site that is tattooed.
Study: NCT03294590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OHT Parent targeted text messages
Description: For the Oral health text message (OHT) group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to oral health.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CWT Parent targeted text messages
Description: For the CWT group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to child wellness.
Study: NCT03232346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivitrol
Description: Oral naltrexone induction procedure followed by Vivitrol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: 5-week buprenorphine taper
Study: NCT04601012

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography
Description: Each subject underwent optical coherence tomography angiography to evaluate the retinal vessel density.

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography
Description: Each subject underwent optical coherence tomography angiography to evaluate the retinal vessel density.
Study: NCT02686385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
Study: NCT00411749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)
Description: V501; Gardasil, 0.5 ml injection in 3 dosing regimen

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: Placebo 0.5 ml injection in 3 dosing regimen
Study: NCT03187132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Pain Reduction Kit
Description: A two-component intervention consisting of (1) virtual reality, experiences lasting 3-30 minutes used to distract individuals from pain and to teach skills related to chronic pain; (2) TENS unit, used to reduce acute localized pain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: An active control TENS unit used to reduce acute localized pain.
Study: NCT02178761

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug-eluting balloon
Description: angioplasty completed with drug-eluting balloons

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biodegradable vascular scaffold stent
Description: Stenting with biodegradable vascular scaffold stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apex™ PTCA Dilatation Catheter
Description: plain old balloon angioplasty alone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent System
Description: stenting with either bare-metal stents or drug-eluting stents
Study: NCT01225094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin
Description: Patients will take the study medication (500 mg x 4 capsules, twice daily \[BID\]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg and then another 2000 mg dose 6 hours after the repair. Final dose is administered the morning after repair.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
Study: NCT04006093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban Oral
Description: one Tablet 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban Oral
Description: one Tablet 5mg
Study: NCT01509755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Once daily injection, under the skin (s.c.) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once daily injection, under the skin (s.c.) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Once daily injection, under the skin (s.c.) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Once daily injection, under the skin (s.c.) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Once daily injection, under the skin (s.c.) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Once daily injection, under the skin (s.c.) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Once daily injection, under the skin (s.c.) for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response
Study: NCT04210674

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The traditional medicinal product of Argan spinosa oil
Description: All children were randomly divided into two groups to receive either the traditional medicinal product of Argan spinosa oil or The conventional topical steroid ointment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The traditional medicinal product of Argan spinosa oil
Description: All children were randomly divided into two groups to receive either the traditional medicinal product of Argan spinosa oil or The conventional topical steroid ointment.
Study: NCT02098798

Intervention type: PROCEDURE
Intervention: HD Colonoscopy
Description: High definition colonoscopy procedure in surveillance colonoscopy

Intervention type: PROCEDURE
Intervention: HD Colonoscopy + iSCAN

Intervention type: PROCEDURE
Intervention: HD Colonoscopy + dye spray
Study: NCT02634333

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Prompt Sham
Description: A sham injection (syringe without a needle pressed against the injection site) is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prompt aflibercept
Description: Intravitreal injection of 2.0mg aflibercept is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Deferred laser
Description: Laser (either focal/grid laser for diabetic macular edema or panretinal photocoagulation for proliferative diabetic retinopathy) is added following initiation of anti-vascular endothelial growth factor injections for center-involved diabetic macular edema or proliferative diabetic retinopathy only if certain criteria are met

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deferred laser
Description: Laser (either focal/grid laser for diabetic macular edema or panretinal photocoagulation for proliferative diabetic retinopathy) is added following initiation of anti-vascular endothelial growth factor injections for center-involved diabetic macular edema or proliferative diabetic retinopathy only if certain criteria are met

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Deferred aflibercept
Description: Intravitreal injection of 2.0mg aflibercept performed once proliferative diabetic retinopathy or center-involved diabetic macular edema develops and then up to every 4 weeks using defined treatment criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferred aflibercept
Description: Intravitreal injection of 2.0mg aflibercept performed once proliferative diabetic retinopathy or center-involved diabetic macular edema develops and then up to every 4 weeks using defined treatment criteria.
Study: NCT01094678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® PTX™ Stent
Description: Stenting of the superfemoropopliteal artery.
Study: NCT00415129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 inactivated, split-virion influenza virus
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 inactivated, split-virion influenza virus
Description: 0.5mL, Intramuscular
Study: NCT02170610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Study: NCT03913949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: Multiple dose cohorts, PO, every day (QD) of a 28-day cycle
Study: NCT01004367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Environmental- and individual based components carried out in the school.
Study: NCT01016184

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Oral vitamin D 100,000 IU
Study: NCT02438228

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac output measurement
Description: Measurement of cardiac output by transpulmonary thermodilution, nine different pulse contour algorithms and esophageal doppler before, during and after a PLR-maneouvre and every 10 minutes before and after cardiopulmonary Bypass.
Study: NCT00670228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine (LANTUS)
Description: Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glulisine (Apidra)
Description: Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard insulin therapy titrated to blood sugar control
Study: NCT02757079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-15
Description: NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
Study: NCT03156010

Intervention type: DEVICE
Group type: OTHER
Intervention: Neuro Kinetics IPAS
Description: Testing with PAS device

Intervention type: DEVICE
Group type: OTHER
Intervention: Neuro Kinetics IPAS
Description: Testing with PAS device

Intervention type: DEVICE
Group type: OTHER
Intervention: Oculogica EyeBox
Description: Testing with Oculogica EyeBox device

Intervention type: DEVICE
Group type: OTHER
Intervention: Oculogica EyeBox
Description: Testing with Oculogica EyeBox device
Study: NCT01016184

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04113746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better asthma self-management and incorporation of physical activity
Description: Participants in the asthma and exercise lifestyle change arm will participate in 4 sessions focused on behavioral change and goal-setting education to teach them how to better incorporate exercise into their daily lives and better manage their asthma. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Asthma Education
Description: General asthma education, but no discussion of the role of exercise and other lifestyle habits in asthma self-management. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
Study: NCT03156010

Intervention type: DEVICE
Group type: OTHER
Intervention: SyncThink EyeSync Device
Description: Testing with SyncThink EyeSync device
Study: NCT01072149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF)/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00376935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Keratinocyte growth factor administered via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Keratinocyte growth factor administered via injection
Study: NCT03438890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warm saline
Description: In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anti-fog agent
Description: In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
Study: NCT02171481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate polymorph II

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate polymorph I
Study: NCT02805530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First line systemic treatment
Description: Epidermal growth factor receptor (EGFR)-mutated with tyrosine kinase inhibitors (afatinib, erlotinib or gefitinib). Patients without driver mutation duplet of chemotherapy based on platin taking account histologic subtype (Carboplatin or Cisplatin plus pemetrexed for adenocarcinomas, gemcitabine for epidermoid or paclitaxel for both) at discretion of the treating physician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radical treatment
Description: to the primary and to the metastases will be with surgery, radiotherapy, chemoradiotherapy, stereotactic radiosurgery or radiofrequency ablation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients will receive dose and fraction regimen according to the metastatic site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Chemoradiotherapy with duplet based on platins (Carboplatin or cisplatin plus pemetrexed or paclitaxel or etoposide or vinorelbine) or monotherapy with carboplatin.
Study: NCT00376935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Keratinocyte growth factor administered via injection